BR9406007A - Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano - Google Patents

Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano

Info

Publication number
BR9406007A
BR9406007A BR9406007A BR9406007A BR9406007A BR 9406007 A BR9406007 A BR 9406007A BR 9406007 A BR9406007 A BR 9406007A BR 9406007 A BR9406007 A BR 9406007A BR 9406007 A BR9406007 A BR 9406007A
Authority
BR
Brazil
Prior art keywords
influenza virus
infection
virus gene
human influenza
gene
Prior art date
Application number
BR9406007A
Other languages
English (en)
Inventor
John J Donnelly
Varavani J Dwarki
Margaret A Liu
Donna L Montgomery
Suezanne E Parker
John W Shiver
Jeffrey B Ulmer
Original Assignee
Merck & Co Inc
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Vical Inc filed Critical Merck & Co Inc
Publication of BR9406007A publication Critical patent/BR9406007A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR9406007A 1993-03-18 1994-03-14 Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano BR9406007A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3238393A 1993-03-18 1993-03-18
US8998593A 1993-07-08 1993-07-08
PCT/US1994/002751 WO1994021797A1 (en) 1993-03-18 1994-03-14 Nucleic acid pharmaceuticals

Publications (1)

Publication Number Publication Date
BR9406007A true BR9406007A (pt) 1996-01-02

Family

ID=26708344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9406007A BR9406007A (pt) 1993-03-18 1994-03-14 Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano

Country Status (22)

Country Link
EP (1) EP0620277A1 (pt)
JP (2) JP2812352B2 (pt)
CN (1) CN1119458A (pt)
AU (1) AU676258B2 (pt)
BG (1) BG63126B1 (pt)
BR (1) BR9406007A (pt)
CA (1) CA2119175A1 (pt)
CZ (1) CZ290315B6 (pt)
DZ (1) DZ1759A1 (pt)
FI (1) FI954329A (pt)
HR (1) HRP940175A2 (pt)
HU (1) HUT73397A (pt)
IL (1) IL108915A0 (pt)
NO (1) NO953649L (pt)
NZ (1) NZ263680A (pt)
PL (1) PL178626B1 (pt)
RO (1) RO117710B1 (pt)
SI (1) SI9420014A (pt)
SK (1) SK114295A3 (pt)
UA (1) UA42715C2 (pt)
WO (1) WO1994021797A1 (pt)
YU (1) YU12894A (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6017897A (en) * 1995-06-07 2000-01-25 Pasteur Merieux Connaught Canada Nucleic acid respiratory syncytial virus vaccines
US6083925A (en) 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US6204250B1 (en) 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
JP2001515468A (ja) * 1997-02-14 2001-09-18 メルク エンド カンパニー インコーポレーテッド ポリヌクレオチドワクチン製剤
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7022320B1 (en) 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
JP4540033B2 (ja) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および/または増強する方法
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
ATE513913T1 (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
JP2010528619A (ja) * 2007-05-31 2010-08-26 ベクトン・ディキンソン・アンド・カンパニー インフルエンザaおよびインフルエンザbウイルスを検出するための配列および方法
US8354230B2 (en) * 2007-12-21 2013-01-15 Quest Diagnostics Investments Inc. Multiplex detection assay for influenza and RSV viruses
CA2733356C (en) 2008-08-01 2016-06-07 Gamma Vaccines Pty Limited Influenza vaccines
WO2010127252A2 (en) * 2009-04-30 2010-11-04 Vanderbilt University Monoclonal antibodies to influenza h1n1 virus and uses thereof
SG168423A1 (en) * 2009-07-13 2011-02-28 Agency Science Tech & Res Influenza detection method and kit therefor
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
US10383835B2 (en) 2012-03-14 2019-08-20 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
EP2976357B1 (en) * 2013-03-18 2018-10-17 Osivax SAS Influenza nucleoprotein vaccines
BR112016006192A2 (pt) 2013-09-25 2017-09-26 Zoetis Services Llc composição de vacina de divergente de pcv2b e métodos de uso
JP6395855B2 (ja) 2014-04-03 2018-09-26 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタ流行性下痢ウイルスワクチン
DK3344289T3 (da) 2015-08-31 2020-04-14 Boehringer Ingelheim Vetmedica Gmbh Pestivirusvacciner mod medfødt tremor
JP2018526454A (ja) 2015-09-16 2018-09-13 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタコレラ菌−ネズミチフス菌ワクチン
KR102618843B1 (ko) 2016-09-20 2024-01-02 베링거잉겔하임베트메디카게엠베하 신규한 ehv 삽입 부위 orf70
BR112019005418A2 (pt) 2016-09-20 2019-10-01 Boehringer Ingelheim Vetmedica Gmbh novos promotores
WO2018057441A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
KR102566066B1 (ko) 2016-09-20 2023-08-16 베링거잉겔하임베트메디카게엠베하 신규한 돼지 인플루엔자 백신
CA3042584A1 (en) 2016-11-03 2018-05-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
BR112019009133A2 (pt) 2016-11-03 2019-07-16 Boehringer Ingelheim Vetmedica Gmbh vacina contra o parvovírus suíno
CN110545841A (zh) 2017-01-30 2019-12-06 勃林格殷格翰动物保健美国有限公司 猪冠状病毒疫苗
KR20200027479A (ko) 2017-07-12 2020-03-12 베링거 인겔하임 애니멀 헬스 유에스에이 인크. 세네카바이러스 a 면역원성 조성물 및 이의 방법
AR113124A1 (es) 2017-09-23 2020-01-29 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresión de paramyxoviridae
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
WO2019162294A1 (en) 2018-02-23 2019-08-29 Boehringer Ingelheim Vetmedica Gmbh Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
AU2019239552A1 (en) 2018-03-19 2020-09-10 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site UL43
EP3768307A1 (en) 2018-03-19 2021-01-27 Boehringer Ingelheim Vetmedica GmbH New ehv with inactivated ul18 and/or ul8
EA202092216A1 (ru) 2018-03-26 2021-06-11 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Способ получения иммуногенной композиции
CN112867505B (zh) 2018-09-20 2024-10-01 勃林格殷格翰动物保健有限公司 经修饰的pedv刺突蛋白
EP3852800A1 (en) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasal vector vaccine against porcine epidemic diarrhea
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
WO2021158878A1 (en) 2020-02-06 2021-08-12 Boehringer Ingelheim Animal Health USA Inc. Polypeptides useful for detecting anti-rhabdovirus antibodies
EP4225776A1 (en) 2020-10-05 2023-08-16 Boehringer Ingelheim Vetmedica GmbH Fusion protein useful for vaccination against rotavirus
CN116438202A (zh) 2020-10-05 2023-07-14 勃林格殷格翰动物保健美国有限公司 包含圆环病毒科衣壳蛋白的融合蛋白及其构成的嵌合病毒样颗粒
AR128992A1 (es) 2022-04-05 2024-07-03 Boehringer Ingelheim Vetmedica Gmbh Composición inmunógena útil para la vacunación contra el rotavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86354A0 (en) * 1987-05-22 1988-11-15 Orion Yhtymae Oy Episomal vector for the expression of selected dna fragments coding for optional polypeptides in mammalian cells and methods for the production thereof
ATE165516T1 (de) * 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit

Also Published As

Publication number Publication date
FI954329A0 (fi) 1995-09-14
PL178626B1 (pl) 2000-05-31
CZ290315B6 (cs) 2002-07-17
YU12894A (sh) 1997-12-05
UA42715C2 (uk) 2001-11-15
PL310677A1 (en) 1995-12-27
AU5788994A (en) 1994-09-22
NZ263680A (en) 1997-05-26
EP0620277A1 (en) 1994-10-19
BG63126B1 (bg) 2001-04-30
BG100006A (bg) 1996-12-31
HRP940175A2 (en) 1997-04-30
SI9420014A (en) 1996-08-31
JPH0795888A (ja) 1995-04-11
HUT73397A (en) 1996-07-29
HU9502702D0 (en) 1995-11-28
CA2119175A1 (en) 1994-09-19
CN1119458A (zh) 1996-03-27
CZ237395A3 (en) 1996-02-14
NO953649L (no) 1995-11-17
JPH10113194A (ja) 1998-05-06
JP2812352B2 (ja) 1998-10-22
SK114295A3 (en) 1996-02-07
WO1994021797A1 (en) 1994-09-29
JP3608642B2 (ja) 2005-01-12
DZ1759A1 (fr) 2002-02-17
FI954329A (fi) 1995-09-14
IL108915A0 (en) 1994-06-24
RO117710B1 (ro) 2002-06-28
NO953649D0 (no) 1995-09-15
AU676258B2 (en) 1997-03-06

Similar Documents

Publication Publication Date Title
BR9406007A (pt) Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano
Swayne et al. Vaccines protect chickens against H5 highly pathogenic avian influenza in the face of genetic changes in field viruses over multiple years
ATE342916T1 (de) Synthetische hiv gag gene
BR9801015A (pt) Vacina de antìgeno de superfìcie contra gripe, e, processo para a preparação de proteìnas de antìgeno de superfìcie de vìrus de gripe preparados em uma cultura de célula animal.
BR9106751A (pt) Oligonucleotideo ou analogo de nucleotideo e processo para modulacao da atividade de uma infeccao por citomegalovirus
HUP9903822A2 (hu) Polinukleotid-vakcinakészítmény sertések szaporodásbiológiai és légzőszervi kórképei ellen
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ES2151506T3 (es) Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos.
PT1212358E (pt) Genes sinteticos de papilomavirus humano
WO2000066739A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
Qiao et al. Vaccines developed for H5 highly pathogenic avian influenza in China
DE69732029D1 (de) Dna enthaltende impfstoffen
Oveissi et al. DNA vaccine encoding avian influenza virus H5 and Esat-6 of Mycobacterium tuberculosis improved antibody responses against AIV in chickens
Hilleman Immunologic, chemotherapeutic and interferon approaches to control of viral disease
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
BR9509076A (pt) Molécula de dna isolada e purificada vetor de expressão proteína anticorpo monoespecífico composto composição farmacêutica vacina e processos para expressar preteina de papilomavírus humano tipo 6a para identificar compostos e para induzir respostas imunes contra infecção ou doença provocada por papilomavírus humano
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
DE60117053D1 (de) Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten
BR9707400A (pt) Vacinas contra produto do gene 63 de vìrus varicella zoster.
Palese et al. Structure, Genetic structure and genetic variation of influenza viruses
NO965017L (no) Oligonukleotider med anti-cytomegalovirus aktivitet
MY101874A (en) Vaccine
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal